Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
| 대상 질환 | Invasive Breast Cancer |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Medical College of Wisconsin |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 36 명 |
| 중재(약물) | Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide |
| 시작일 | 2020년 3월 5일 |
| 완료일 | 2025년 8월 11일 |
| 결과 공개일 | 2026년 7월 27일 |
요약
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or hormone receptor-negative (HR-) (estrogen-receptor-negative (ER-) and progesterone-receptor-negative (PR-) human epidermal growth factor receptor 2 (HER2) negative/triple-negative breast cancer.
The Proportion of Breast Cancer Patients With Pathological Complete Response (pCR).
| Drug Treatment | 24.2 percentage of subjects |
|---|---|
| Drug Treatment | 75.8 percentage of subjects |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Vitamin D and Physical Activity on Bone Health — University of Rochester
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in T — National Cancer Institute (NCI)
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor — National Cancer Institute (NCI)
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced — National Cancer Institute (NCI)
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Can — AstraZeneca
- Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Adm — University of Colorado, Denver